Apolipoprotein A-I, apolipoprotein B, and apolipoprotein B/apolipoprotein A-I ratio: Reference intervals compared with values in different pathophysiological conditions from the FINRISK 2007 study

In addition to traditional measurements of serum lipid levels, apolipoprotein A-I (apoA-I), apolipoprotein B (apoB), and apoB/apoA-I ratio may add more value to risk assessment guidelines for cardiovascular disease. We calculated reference intervals for apoA-I, apoB, and apoB/apoA-I ratio using a re...

Full description

Saved in:
Bibliographic Details
Published in:Clinica chimica acta 2011-05, Vol.412 (11-12), p.1146-1150
Main Authors: Leiviskä, Jaana, Sundvall, Jouko, Alfthan, Georg, Jauhiainen, Matti, Salomaa, Veikko
Format: Article
Language:English
Subjects:
Adult
Aged
Apolipoprotein
Apolipoprotein A-I - blood
Apolipoproteins B - blood
Blood Chemical Analysis - standards
Disease
Female
Finland
Health Surveys
Humans
Male
Metabolic syndrome
Middle Aged
Obesity
Reference intervals
Reference Values
Risk Assessment
Therapeutic goals
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In addition to traditional measurements of serum lipid levels, apolipoprotein A-I (apoA-I), apolipoprotein B (apoB), and apoB/apoA-I ratio may add more value to risk assessment guidelines for cardiovascular disease. We calculated reference intervals for apoA-I, apoB, and apoB/apoA-I ratio using a reference sample (n=2828) from the FINRISK 2007 study. The reference intervals for apoA-I were 1.1–2.0g/l for men and 1.2–2.3g/l for women. The corresponding reference intervals for apoB were 0.6–1.5g/l and 0.6–1.3g/l. The reference intervals for apoB/apoA-I ratio were 0.3–1.0 for men and 0.3–0.8 for women. Compared with the healthy reference group, obese men had the lowest ApoA-I, the highest apoB, and the highest apoB/apoA-I ratio. Men with CVD and cholesterol-lowering medication, or diabetes had lower apoB levels and apoB/apoA-1 ratio than the reference group but the opposite was true for women. The therapeutic goal for low-risk individuals for apoB was 0.9g/l coinciding with LDL-C concentration of 3.0mmol/l. Reference intervals for apoA-I, apoB, and the apoB/apoA-I ratio and their cutoff values may be useful for the risk evaluation and follow-up of treatment among individuals having CVD or other metabolic disorders.
ISSN:0009-8981
1873-3492
DOI:10.1016/j.cca.2011.03.015